Payment overview · 2025
General Payments
$350.53
18 reported records · 8 companies
Healthcare provider profile · identity verified
Christopher W Ogburn, MD
Allopathic & Osteopathic Physicians|Family Medicine · PRINCE GEORGE, VA · NPI 1023037165
Verified facts
What the public records show
CMS Open Payments records show Christopher W Ogburn, MD received $350.53 in general payments during 2025 across 18 reported records.
PFIZER INC. accounted for 46.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Qulipta, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $161.42 | 46.0% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $63.24 | 18.0% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.14 | 8.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.12 | 6.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.58 | 5.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.35 | 5.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.05 | 5.2% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $17.63 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $350.53 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $94.62 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $94.62 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $66.80 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $66.80 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $66.80 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $30.14 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $30.14 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $30.14 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
217 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1078 | 263 |
| Amlodipine Besylate | Amlodipine Besylate | 750 | 200 |
| Levothyroxine Sodium | Levothyroxine Sodium | 643 | 145 |
| Omeprazole | Omeprazole | 579 | 161 |
| Lisinopril | Lisinopril | 546 | 130 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 448 | 104 |
| Losartan Potassium | Losartan Potassium | 445 | 115 |
| Metformin Hcl Er | Metformin Hcl | 433 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 413 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 364 | 91 |
| Gabapentin | Gabapentin | 299 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 280 | 83 |
| Montelukast Sodium | Montelukast Sodium | 275 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 272 | 80 |
| Pravastatin Sodium | Pravastatin Sodium | 248 | 64 |
| Sertraline Hcl | Sertraline Hcl | 231 | 56 |
| Simvastatin | Simvastatin | 224 | 48 |
| Eliquis | Apixaban | 217 | 42 |
| Furosemide | Furosemide | 213 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 63 |
| Prednisone | Prednisone | 209 | 123 |
| Spironolactone | Spironolactone | 209 | 58 |
| Famotidine | Famotidine | 208 | 65 |
| Diclofenac Sodium | Diclofenac Sodium | 204 | 109 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 200 | 57 |
| Metformin Hcl | Metformin Hcl | 200 | 52 |
| Pioglitazone Hcl | Pioglitazone Hcl | 200 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 199 | 52 |
| Carvedilol | Carvedilol | 182 | 44 |
| Trazodone Hcl | Trazodone Hcl | 179 | 47 |
| Clonazepam | Clonazepam | 175 | 34 |
| Allopurinol | Allopurinol | 173 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 43 |
| Potassium Chloride | Potassium Chloride | 141 | 34 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 139 | 109 |
| Tizanidine Hcl | Tizanidine Hcl | 139 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 37 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 137 | 35 |
| Finasteride | Finasteride | 132 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 132 | 31 |
| Glimepiride | Glimepiride | 128 | 36 |
| Alprazolam | Alprazolam | 116 | 22 |
| Jardiance | Empagliflozin | 116 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 113 | 27 |
| Methylprednisolone | Methylprednisolone | 111 | 83 |
| Bupropion Xl | Bupropion Hcl | 108 | 28 |
| Lovastatin | Lovastatin | 106 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 34 |
| Mirtazapine | Mirtazapine | 97 | 29 |
| Tramadol Hcl | Tramadol Hcl | 96 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 96 | 49 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 35 |
| Donepezil Hcl | Donepezil Hcl | 90 | 28 |
| Nifedipine Er | Nifedipine | 88 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 20 |
| Warfarin Sodium | Warfarin Sodium | 87 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 83 | 61 |
| Pregabalin | Pregabalin | 79 | 24 |
| Alendronate Sodium | Alendronate Sodium | 78 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 21 |
| Synthroid | Levothyroxine Sodium | 72 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 20 |
| Memantine Hcl | Memantine Hcl | 71 | 15 |
| Ozempic | Semaglutide | 67 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 17 |
| Estradiol | Estradiol | 63 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 63 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | suppressed |
| Topiramate | Topiramate | 62 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 13 |
| Torsemide | Torsemide | 60 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 59 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 16 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 57 | 14 |
| Atenolol | Atenolol | 53 | 14 |
| Xarelto | Rivaroxaban | 53 | 12 |
| Lansoprazole | Lansoprazole | 51 | 11 |
| Meloxicam | Meloxicam | 51 | 13 |
| Primidone | Primidone | 51 | suppressed |
| Ondansetron Odt | Ondansetron | 50 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 15 |
| Buspirone Hcl | Buspirone Hcl | 43 | 13 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | 18 |
| Baclofen | Baclofen | 40 | suppressed |
| Cephalexin | Cephalexin | 40 | 34 |
| Temazepam | Temazepam | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Creon | Lipase/Protease/Amylase | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | 11 |
| Colchicine | Colchicine | 32 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Ketoconazole | Ketoconazole | 32 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 16 |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 12 |
| Valsartan | Valsartan | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 18 |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 14 |
| Mupirocin | Mupirocin | 24 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 14 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Sulindac | Sulindac | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 17 |
| Irbesartan | Irbesartan | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Methimazole | Methimazole | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Celexa | Citalopram Hydrobromide | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Sotalol Af | Sotalol Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $350.53 · 18 records | PFIZER INC. | ABRYSVO, AIRSUPRA, CAPVAXIVE, COMIRNATY, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), GARDASIL 9, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, UBRELVY, VAXNEUVANCE, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error